IL-7, initially described as a B-lineage growth factor, has been demonstrated to stimulate proliferation and induce signal transduction events in both B and T-cell progenitors, myeloid cells, mature T-cells, and a variety of patients leukemia and lymphoma cells. Recent studies have demonstrated that the IL7R complex consists of at least two subunits, one being a p64 protein shared among the IL2R, Il4R and IL7R complexes. Intracellular events associated with IL7R engagement include tyrosine phosphorylation on a number of proteins, stimulation of phosphatidylinositol kinase, and induction of expression of a number of early response genes, including c-myc and c-jun. The recent demonstration of constitutive IL7 secretion and development of IL7R antagonist agents might b of clinical use in the therapy of a variety of hematopoietic neoplasms. To date, different IL7 receptor isoforms have been identified in the context of resting and activated normal T-lymphocytes, but isoform composition and its relationship to receptor affinity aha not been clearly defined in neoplastic lymphocytes.
The aim of this proposal is to further characterize the native IL7R isoforms and biological correlates of ligand- receptor binding on neoplastic lymphocytes from a series of patients with leukemias and lymphomas. In order to better understand properties of the ligand and its receptor important to its biological activity, a number of candidate IL7 mutants will be utilized, to define the receptor-binding and signal transducing domains of the cytokine, and a series of chimeric ligand fusion toxins will be used to define the requirements for ligand-receptor internalization in both normal and neoplastic lymphocytes. This work will be conducted in collaboration with Dr. John Murphy, who will generate the candidate mutants and fusion toxins.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA048626-09
Application #
6102504
Study Section
Project Start
1998-09-01
Project End
1999-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
9
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Boston Medical Center
Department
Type
DUNS #
005492160
City
Boston
State
MA
Country
United States
Zip Code
02118
Cosenza, Larry; Gorgun, Gullu; Urbano, Alexander et al. (2002) Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell Signal 14:317-25
vanderSpek, Johanna C; Sutherland, John A; Gill, Brian M et al. (2002) Structure function analysis of interleukin 7: requirement for an aromatic ring at position 143 of helix D. Cytokine 17:227-33
Gorgun, Gullu; van der Spek, Johanna; Cosenza, Larry et al. (2002) Altered biological activity associated with C-terminal modifications of IL-7. Cytokine 20:17-22
Sweeney, E B; Foss, F M; Murphy, J R et al. (1998) Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells. Bioconjug Chem 9:201-7
Kelley, V R; Strom, T B (1995) A paradigm 1994: the allograft response. Blood Purif 13:199-205
Kelley, V R; Singer, G G (1993) The antigen presentation function of renal tubular epithelial cells. Exp Nephrol 1:102-11
Jevnikar, A M; Singer, G G; Coffman, T et al. (1993) Transgenic tubular cell expression of class II is insufficient to initiate immune renal injury. J Am Soc Nephrol 3:1972-7
Bloom, R D; Florquin, S; Singer, G G et al. (1993) Colony stimulating factor-1 in the induction of lupus nephritis. Kidney Int 43:1000-9
Singer, G G; Yokoyama, H; Bloom, R D et al. (1993) Stimulated renal tubular epithelial cells induce anergy in CD4+ T cells. Kidney Int 44:1030-5
Diaz-Gallo, C; Kelley, V R (1993) Self-regulation of autoreactive kidney-infiltrating T cells in MRL-lpr nephritis. Kidney Int 44:692-9

Showing the most recent 10 out of 29 publications